NASDAQ$BCAB
Bioatla Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
BioAtla achieved key milestones in clinical programs and reported financial results.
BioAtla reported a net loss of $35.8 million for the second quarter of 2023, compared to a net loss of $28.9 million for the same quarter in 2022. The company's cash and cash equivalents were $168.7 million as of June 30, 2023, expected to provide funding into 2025.
- Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS).
- Submitted Food & Drug Administration (FDA) meeting request for potentially registrational study of BA3011 in non-small cell lung cancer (NSCLC) study; FDA feedback and initiation of study remain on track for 2H23.
- Cleared fifth cohort at 5 mg/kg monotherapy and in combination with PD-1 in Phase 1 dose-escalation CAB-CTLA-4 (BA3071) study with no dose-limiting toxicities (DLTs) reported.
- Cash balance of $168.7 million expected to provide funding into 2025.
Headline financials
Revenue & EPS history
Bioatla · Revenue · Quarterly
$0
Forward guidance
BioAtla anticipates several important near-term value inflection points, including data readouts in the second half of this year. The company also expects FDA feedback for its Phase 2, part 2 potentially registrational BA3011 trial in NSCLC, and initiation of its Phase 2 CAB-CTLA-4 BA3071 trial in multiple indications.
Tailwinds
- LMS cohort data readout remains on track for 2H23 using a more frequent, dose-intensive regimens
- Anticipate FDA feedback in 2H23 for the BA3011 study design
- Initiation of BA3011 study on track for 2H23
- Phase 2 investigator-initiated trial is on track with interim data (n=10) anticipated in 2H23
- Anticipated Phase 1 data readout remains on track for 2H23
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+5.5%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+7.5%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+76.7%
Q2 2022
Best reaction
-37.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -18.1% | -15.1% | |
| Q3 2025 | +23.2% | +75.8% | +24.8% | |
| Q2 2025 | -5.6% | +3.2% | +41.3% | |
| Q1 2025 | -7.2% | -9.1% | +1.5% | |
| Q4 2024 | -4.9% | -13.5% | +12.2% | |
| Q3 2024 | +1.9% | +6.3% | -20.4% | |
| Q2 2024 | +5.8% | +0.7% | +25.2% | |
| Q1 2024 | +13.6% | +7.2% | -40.5% | |
| Q4 2023 | +48.5% | +47.6% | -3.4% | |
| Q3 2023 | -10.3% | -24.2% | -15.8% | |
| Q2 2023 | -0.3% | -8.4% | -16.1% | |
| Q1 2023 | +10.9% | +7.9% | +10.3% | |
| Q4 2022 | +0.9% | +0.4% | +48.3% | |
| Q3 2022 | +17.1% | +22.8% | +63.1% | |
| Q2 2022 | +76.7% | +86.9% | +142.2% | |
| Q1 2022 | -37.3% | -43.9% | -28.2% | |
| Q4 2021 | +1.9% | -15.1% | -22.8% | |
| Q3 2021 | -0.3% | -1.9% | -24.5% | |
| Q2 2021 | -4.4% | -2.7% | -9.4% | |
| Q1 2021 | -2.4% | -1.9% | +6.6% | |
| Q4 2020 | -10.6% | -21.5% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro